Puretech Health Plc (PRTC) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Bristol Myers Squibb has completed the acquisition of Karuna Therapeutics, a PureTech Health founded entity, for $14 billion, focusing on the schizophrenia treatment KarXT. PureTech is set to receive approximately $293 million from its equity in Karuna, alongside potential milestones and royalties from KarXT’s future successes. The deal marks a significant advancement for PureTech and promises to reshape treatment options for schizophrenia patients.
For further insights into PRTC stock, check out TipRanks’ Stock Analysis page.
